Celldex Therapeutics Gross Profit 2010-2022 | CLDX

Celldex Therapeutics gross profit from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Celldex Therapeutics Annual Gross Profit
(Millions of US $)
2021 $5
2020 $7
2019 $4
2018 $10
2017 $13
2016 $7
2015 $5
2014 $4
2013 $2
2012 $0
2011 $0
2010 $35
2009 $7
Celldex Therapeutics Quarterly Gross Profit
(Millions of US $)
2022-03-31 $0
2021-12-31 $0
2021-09-30 $0
2021-06-30 $3
2021-03-31 $1
2020-12-31 $4
2020-09-30 $1
2020-06-30 $0
2020-03-31 $3
2019-12-31 $1
2019-09-30 $1
2019-06-30 $1
2019-03-31 $1
2018-12-31 $2
2018-09-30 $1
2018-06-30 $3
2018-03-31 $4
2017-12-31 $3
2017-09-30 $4
2017-06-30 $4
2017-03-31 $2
2016-12-31 $2
2016-09-30 $2
2016-06-30 $1
2016-03-31 $1
2015-12-31 $2
2015-09-30 $1
2015-06-30 $2
2015-03-31 $0
2014-12-31 $1
2014-09-30 $1
2014-06-30 $1
2014-03-31 $0
2013-12-31 $1
2013-09-30 $1
2013-06-30 $0
2013-03-31 $0
2012-12-31 $0
2012-09-30 $0
2012-06-30 $0
2012-03-31 $0
2011-12-31 $0
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $31
2010-09-30 $1
2010-06-30 $1
2010-03-31 $1
2009-12-31 $2
2009-09-30 $2
2009-06-30 $1
2009-03-31 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.262B $0.005B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00